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Introduction: Informed, voluntary, and valid consent from biomaterial donors is a
precondition for biobank research. Valid consent protects donors’ rights and helps maintain
public trust in biobank research. Harmonization of consent procedures in biobank research
is needed, because of the widely shared vision on national and international networking of
biobanks including data and sample sharing. So far, no study has assessed and compared
the content of current consent forms especially for biobank research. The objective of this
study was to perform a content analysis of consent forms in German biobanks.
Methods: Based on ten guidelines for biomedical research, we developed an assessment
matrix with 41 content issues that are potentially relevant for consent forms in biobank
research. This assessment matrix was applied in a thematic text analysis to 30 consent
documents of German biobanks identiﬁed via the German Biobank Registry in July 2012.
Results: Coverage of the 41 items in the assessed consent forms varied widely. For
example, the items “Right towithdraw consent (without disadvantage),” “Policy for genetic
information/consent to genetic analyzes” and “International cooperation/transborder use”
were addressed in 97, 40, and 23% of all 30 consent forms respectively. The number of
items covered by a single consent form ranged from 9 to 36 (22–88% out of 41 items).
Discussion:Our ﬁndings serve as a starting point to reﬂect upon the spectrum of consent
issues that must be addressed in biobank research. The ﬁndings show that the majority of
consent forms for German biobanks, if not all, should be improved and harmonized to better
support an informed and balanced choice of potential donors and to facilitate networking of
biobanks. Best practice models for consent forms in biobank research should be developed
and biobank operators need to be more aware of relevant consent issues.
Keywords: biobank, tissue bank, broad consent, informed consent, survey, thematic text analysis, research ethics
INTRODUCTION
Biobanks are collections of human biological samples and related
health/personal information. A high quality biobank that orga-
nizes samples for use by biomedical researchers is seen as an
important resource for health research, including basic research,
questions in personalized or stratiﬁed medicine (genetic and other
biomarkers), and research in widespread diseases (Asslaber and
Zatloukal, 2007; Zika et al., 2010).
The development of large-scale population-based as well as
disease-speciﬁc biobanks also implies several new ethical, legal
and social challenges. These comprise, e.g., issues around the role
of ethics committees, data protection, dealingwith incidental ﬁnd-
ings, public involvement measures, and particularly regarding the
need for new or at least modiﬁed models of informed consent
of the donors (Budimir et al., 2011; Gottweis and Kaye, 2012).
As acquired for diagnostic and therapeutic procedures in clini-
cal as well as in research settings, informed, voluntary, and valid
consent is a precondition for the collection of samples and clin-
ical data of donors in a biobank. It also tends to protect donors’
rights and autonomy and to maintain public trust in biobank
research. Crucial points include the scope and content of consent
forms, for example, how do consent forms address potential future
research projects that might involve the donated biomaterials
(broad/general vs. narrow/speciﬁc consent) (Cambon-Thomsen
et al., 2007; Greely, 2007; Hansson, 2009; OECD, 2009; Budimir
et al., 2011; Deutscher Ethikrat, 2011). Additionally, biobank
research consent procedures and documentation involve different
or additional aspects compared with clinical research, e.g., con-
cerning data protection and data sharing with other researchers
(Hoeyer et al., 2005; Beskow et al., 2010; McGuire and Beskow,
2010; Pawlikowski et al., 2011). Besides, the harmonization of
consent templates, at least of the most important criteria, is essen-
tial for future cooperation and networking at the national and
international level.
Though information and consent documents do certainly
not substitute the discussion between clinician/researcher and
patient/participant, they are an important component within the
informed consent procedure and its documentation, as well as
for legal aspects. Regarding quality and performance of consent
forms in clinical or research contexts, several empirical stud-
ies demonstrated that consent forms are often not adequate in
content, comprehensibility or practicability and do not meet
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participants’ needs. Improvements are necessary within consent
procedure and documents to support an adequately well-balanced
and evidence-based decision-making process by participants (Jef-
ford and Moore, 2008; Padhy et al., 2011; Brehaut et al., 2012;
Mandava et al., 2012).
Several sets of ethical guidance deﬁne the required criteria for
consent in clinical research, e.g., (Council for International Orga-
nizations of Medical Sciences [CIOMS], 2002; World Medical
Association [WMA], 2008). Some guidelines also explicitly men-
tion required criteria for consent in biobank research, e.g., (OECD,
2009). Nevertheless, there is no speciﬁc guidance for biobank
research and consent procedures that can be employed as a tool
for the assessment of consent forms’ content in clinical or biobank
research. Furthermore, we currently lack a broadly accepted “best
practice” model for consent forms in biobank research (Gottweis
and Kaye, 2012).
Also in Germany, the number and importance of biobank facil-
ities and projects with similar requirements is increasing, e.g., in
population-wide studies such as KoraGEN and PopGEN, and the
National Biobank Initiative (“Nationale Biomaterialbanken Ini-
tiative”) funded by the German Federal Ministry of Education
and Research (Bundesministerium für Bildung und Forschung,
BMBF).
Existing studies that describe different biobanks and their gov-
ernance strategies also indicate challenges in consent procedures
(Hirtzlin et al., 2003; Zika et al., 2010; Gottweis and Kaye, 2012).
Some research groups propose a uniﬁed consent model or possi-
ble content for a consent form in biobank research (Porteri and
Borry, 2008; Salvaterra et al., 2008) or for whole genome sequenc-
ing studies in the clinical context (Ayuso et al., 2013). Besides,
there are studies comparing participant information and consent
forms in genetic research (Mascalzoni et al., 2010) or in clinical
trials (Hüppe et al., 2013). But so far, no study has assessed and
compared the content of consent forms for biobank research. The
objective of this studywas to perform a survey and content analysis
of currently used consent forms in German biobanks.
MATERIALS AND METHODS
To improve the comprehensiveness, reliability, validity, and objec-
tivity of our assessment of biobank speciﬁc consent forms, we ﬁrst
systematically developed an assessment matrix of potentially rel-
evant issues that might be addressed in consent documents for
biobank research. We then applied this assessment matrix to a
sample of consent forms from German biobanks.
DEVELOPMENT OF THE ASSESSMENT MATRIX
To identify issues that might be addressed in consent documents
for biobank research, we referred to frequently cited policies,
guidelines, and regulations dealingwith general recommendations
for consent procedures in biomedical research (mainly clinical
studies) and/or biobank research. More speciﬁcally, we used nine
prominent guidelines for biomedicine (Council of Europe, 1997),
biomedical research with humans in general (European Parlia-
ment and the Council of the European Union, 2001; Council for
International Organizations of Medical Sciences [CIOMS], 2002;
European Medicines Agency [EMEA], 2002; Council of Europe,
2005; World Medical Association [WMA], 2008; US Department
of Health and Human Services, 2009), and biobank or biomaterial
research in particular (Council of Europe, 2006; OECD, 2009).
For the national (German) context, we referred to a “commented
checklist” of issues in patient information and consent for clini-
cal studies with an annex for biobank research (Harnischmacher
et al., 2006). The set of selected guideline is a purposive sam-
ple. Most of the chosen guidelines are, for instance, indicated as
important legal and ethical frameworks in other sources such as
the Oxford Textbook of Clinical Research Ethics (Capron, 2008;
Emanuel et al., 2008).Wehave discussed the selection of guidelines
and the resulting construct validity of the matrix of consent issues
internally and with experts from the ﬁelds of law and biobank
research.
In all ten documents, one author (Irene Hirschberg) searched
for text passages that explicitly or implicitly mentioned issues of
potential relevance to the content of consent forms in biomedical
research in general, and applicable to biobank research. Exam-
ples mentioned as necessary information for consent included
“general procedures and safeguards used to protect privacy and
conﬁdentiality,” the “policy with respect to beneﬁt sharing” and
“information on the human biological material and data to be
collected, their intended uses, storage, transfer and their dis-
posal technique” (OECD, 2009). An example for a relevant but
implicitly mentioned issue dealt with the removal of biologi-
cal materials after death: “biological materials should not be
removed from the body of a deceased person for research activ-
ities without appropriate consent or authorisation.” (Council of
Europe, 2006) Other issues were mentioned only in relation to
the research protocol, such as “incentives for subjects” (World
Medical Association [WMA], 2008),” or came under the discus-
sion of policy, but indicated as relevant to participants: “The
HBGRD’s policy should also address the situation where par-
ticipants become legally incapacitated or die. It is essential that
the HBGRD provide information on their policy to the partici-
pant or the appropriate substitute decision-maker at the time of
consenting.” (OECD, 2009) The results and any ambiguity were
discussed with the other authors (Hannes Knüppel and Daniel
Strech). We excluded generally important aspects of biomedi-
cal research that were mentioned in one or more guidelines but
were not considered relevant to the content of consent forms in
biobank research, e.g., “trial treatment and random assignment
(European Medicines Agency [EMEA], 2002)” and “alternative
procedures or courses of treatment” (US Department of Health
and Human Services, 2009). We also excluded formal aspects such
as “title of the document” or “date/signature” (Harnischmacher
et al., 2006).
We compared the mentions of issues relevant to consent forms
in biobank research in different guidelines, and developed cate-
gories for similar mentions of issues. During the development of
these categories,we slightly adapted the items arising from the clin-
ical study context to the biobank context. For instance, we revised
the wording “duration of participation in trial/study” to “duration
of participation or storage.” In some cases we performed a synthe-
sis of issues, e.g., subsuming “money or material goods” (Council
for International Organizations of Medical Sciences [CIOMS],
2002), “payment” and “expenses” (European Medicines Agency
[EMEA], 2002), “additional costs” (US Department of Health
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and Human Services, 2009), “incentives” (World Medical Asso-
ciation [WMA], 2008), and “allowance” (Harnischmacher et al.,
2006) under “Payment/allowance and additional costs.”We ﬁnally
obtained 41 items grouped under four main headings (see Results
and Table 1). Each of the 41 items derives from at least two
guidance documents.
BIOBANK SURVEY AND ANALYSIS OF THE CONSENT DOCUMENTS
To get an overview of consent documents and templates cur-
rently used in biobank research in Germany, we considered all
biobanks registered in the German Biobank Registry (“Deutsches
Biobanken-Register,” http://www.biobanken.de) in July 2012. We
excluded six of the 108 registered biobanks because they were
either doubly mentioned in the register or did not exist anymore
(or their web site could not be accessed). Nine of the remaining
102 biobanks had consent forms publically available on their web-
sites. We asked the heads of the other 93 biobanks via email to
send us their consent documents. In this email we made clear that
Germanbiobankswill not be named individually in the dissemina-
tion of ﬁndings from our study. The response rate after repeated
contact was 48% (44/90 biobanks, three mailing addresses were
incorrect). Not all biobanks were willing to provide their consent
document; some biobanks used a shared consent form, and two
biobanks provided two documents for different purposes. At last,
we were able to include 30 consent documents of 33 biobanks in
our analysis. If the biobanks provided additional participant infor-
mation and a consent form, we included both documents in the
analysis.
The representation of all 41 items in each of the 30 consent
documents was assessed according to standards in thematic text
analysis (Dixon-Woods et al., 2005). All researchers were experi-
enced in thematic text analysis and research ethics. The consent
forms were read in full by two authors (Irene Hirschberg and
Hannes Knüppel) independently to identify and extract text pas-
sages corresponding to each of the 41 consent issues for biobank
research. For the purpose of this study the authors only rated
whether the items were mentioned or not. For example, the
authors did not evaluate in depth whether these items were suf-
ﬁciently comprehensible. After the independent text extraction
and rating the researchers compared their results. Discrepancies
between the resulting spreadsheets were identiﬁed in 114 (9.3%)
of all 1,230 ratings (41 ratings for each of the 30 consent forms).




Our assessment matrix comprises 41 items in four categories: (A)
“General information” covering, e.g., explanation of the type of
research and its purpose, (B)“Conditions of participation” includ-
ing background on voluntary participation, consent conditions
and scope, (C) “Consequences of participation” comprising items
on, e.g., risks and beneﬁts, and (D)“Dealing with data and bioma-
terial” encompassing items on, e.g., data protection measures and
cooperation with other parties. Table 1 presents the 41 items of
the assessment matrix for consent in biobank research, the num-
ber of guidance sets from which each item derived, and the extent
to which the items were mentioned in the German biobank sample
(see Table 1).
GERMAN CONSENT DOCUMENTS FOR BIOBANK RESEARCH
Our sample comprised 30 consent documents from 33 German
biobanks registered in the German Biobank Registry in July 2012.
The sample includes different types of biobank with varying char-
acteristics as type (population-wide or disease-speciﬁc biobank,
or clinical study with sample collections), number of participants,
organization and funding, and inclusion of healthy probands or
patients (e.g., inclusion of all admitted patients). However, all reg-
istered biobanks are considered to perform biobank research. The
German Biobank Registry is operated by the TMF (Technology,
Methods, and Infrastructure for Networked Medical Research)
and is funded by the German Federal Ministry of Education and
Research.
Most of the biobanks had developed their own consent docu-
ments; one biobank just used a consent form for genetic diagnostic
similar to a template of the German Society of Human Genet-
ics. The consent documents (participant information and consent
form) varied in several characteristics, e.g., in length of document
(one to ﬁve pages), target group (patient, healthy participant, next
kin, children, or parents), scope of consent, content, complexity
and comprehensibility.
The coverage of the 41 items by the 30 consent documents was
very variable. One item (“Right towithdrawor alter consent (with-
out disadvantage)”)was addressed in 97%, another item (“Dealing
with data and material after participants die or become incapac-
itated”) was not addressed by any consent form (see Table 1).
Though for the interpretation of the results, it has to be consid-
ered that a few items – as“Removal of samples after death”– are not
applicable to all biobanks. Nevertheless, in these cases the items
were counted as “not mentioned”.
A large majority of the German consent documents referred
to items as in section (A) such as e.g., “Research explanation and
purpose”(93%) and“Biomaterial: types andquantity of specimen”
(90%), to elementary conditions in (B) such as“Free and voluntary
participation”(80%) or“Right to withdraw or alter consent (with-
out disadvantage)” (97%) and to basic aspects in section (D) such
as “Conﬁdentiality of records and data/extent and limits of conﬁ-
dentiality” (80%) and “Privacy rights and procedures/safeguards,
data processing, and identiﬁability of data and samples” (90%).
Information on some controversially discussed or partly not
foreseeable items was given less frequently e.g., for general infor-
mation (section (A)) such as “Future development and changes”
(30%) or information on “Rights/Ownership of samples and data
and their transfer” (57%). Also some points regarding the condi-
tions of participation (section (B)) were considered by just half of
the documents, e.g., “Decision on participation/withdrawal with-
out affecting medical care or relationship to physician” (50%)
or “Options/partial consent” (53%). Of the items regarding the
consequences of participation (section (C)), the most mentioned
was“Risk”(70%) and the least-mentioned“Payment/Allowance or
additional costs” (33%). The mentioning of risks ranged from: no
anymentioned risks at all overminimal risks for the sample/blood-
taking procedure to a very detailed description of the risks using
genetic data. (The latter refer to for example the knowledge as
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Table 1 | Representation of 41 consent issues for biobank research in 30 German consent documents.
Consent issues for biobank research Origin: mention in guidelines for the
regulation of biomedical research (n = 10)
Application: mention in biobank-specific
consent documents (n = 30)
Assessment items n % n %
(A) General information
Research explanation and purpose 10 100 28 93
Future development and changes 5 50 9 30
Biobank design and structure 5 50 21 70
Funding and (conﬂict of) interests 6 60 6 20
Duration of participation or storage 7 70 15 50
Biomaterial: types and quantity of specimen 3 30 27 90
Data: type and quantity of data 3 30 19 63
Description of collection procedures and
additional tests
8 80 26 87
Sample collection: further examination
needed/follow up-points
2 20 23 77
Rights/ownership of samples and data and
their transfer
2 20 17 57
Opinion or approval of ethical review
board/committee
5 50 16 53
(B) Conditions of participation
Dimension of consent: scope, safeguards and
conditions
4 40 15 50
Free and voluntary participation 10 100 24 80
Right to withdraw or alter consent (without
disadvantage)
10 100 29 97
Withdrawal: modalities and consequences
regarding biomaterial and data
5 50 24 80
Decision on participation/withdrawal without
affecting medical care or relationship to
physician
5 50 15 50
Compensation and insurance cover 7 70 5 17
Options (partial consent) 3 30 16 53
(C) Consequences of participation
Direct beneﬁt for participant 10 100 15 50
Indirect beneﬁt for subgroups or society 10 100 19 63
Risk 10 100 21 70
Payment/allowance or additional costs 5 50 10 33
Beneﬁt-sharing 3 30 18 60
Feedback on ﬁndings or incidental ﬁndings 6 60 20 67
Publication of data only unlinked 2 20 17 57
Re-contacting of participant: purpose and
conditions
4 40 18 60
Contact person/point 5 50 18 60
(Continued)
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Table 1 | Continued
Consent issues for biobank research Origin: mention in guidelines for the
regulation of biomedical research (n = 10)
Application: mention in biobank-specific
consent documents (n = 30)
Assessment items n % n %
(D) Dealing with data and biomaterial
Conﬁdentiality of records and data/extent and
limits of conﬁdentiality
9 90 24 80
Privacy rights and procedures/safeguards, data
processing, and identiﬁability of data and
samples
6 60 27 90
Use of health data and records and their
purpose
3 30 20 67
Storage of data and biomaterial 3 30 20 67
Policy for genetic information/consent to
genetic analyses
2 20 12 40
Contact with or disclosure to participant’s
physician
2 20 19 63
Policy on use/disclosure to third parties for
non-research purpose
3 30 7 23
Sharing data and material with other
researchers/policy and process
2 20 24 80
International cooperation/trans-border use 2 20 7 23
Commercialisation and collaboration with
for-proﬁt entities
5 50 17 57
Right of access to personal data 3 30 5 17
Disposal or destruction of data and material 3 30 21 70
Dealing with data and material after
participants die or become incapacitated
2 20 0 0
Removal of material after death 2 20 1 3
such and the related psychological burdens for the donor or fam-
ily members, implication on re-identiﬁability of “anonymized”
data, and potential implications on health insurance and
employment).
Some items of presumably high importance for biobank
research (in section (D)“Dealing with data and biomaterial”) were
mentioned infrequently, e.g., “International Cooperation/trans-
border use” (23%), “Right of access to personal data” (17%)
or “Policy on use/disclosure to third parties for non-research
purpose” (23%).
The number of items found also varied widely among the 30
consent documents (see Table 2), from a minimum of 9 (22%) to
a maximum of 36 (88%). The median of items addressed across
all 30 consent forms was 25.5 items (62%).
DISCUSSION AND CONCLUSION
This study illustrates that consent documents from 30 German
biobanks differ widely in the range of issues that they address.
Out of 41 potentially relevant issues (systematically identiﬁed in
Table 2 | Distribution of assessment items (n = 41, divided into five
ranges) for consent content in biobank research, found in consent
documents of a German biobank sample (n = 30).
Assessment items for consent
in biobank research
Mention in German biobank
consent documents
Range n %
33–41 (approx. 80–100%) 3 10
25–32 (approx. 60–80%) 14 47
17–24 (approx. 40–60%) 6 20
9–16 (approx. 20–40%) 7 23
0–8 (approx. 0–20%) 0 0
leading guidelines on consent in biomedical research) only three
consent forms (10%) address more than 80% while another seven
consent forms (23%) address less than 40%.
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One should bear in mind that the consideration of more items
does not facilitate consent or increase its validity per se. Neverthe-
less, one should have reasonable motives to minimize the extent
of content and leave out relevant items.
With respect to the existing heterogeneity and different types
of biobanks, it has to be considered that not all of the mentioned
items must be applicable or equally relevant to each biobank.
Nevertheless, core criteria for consent in biobank research and
could be harmonized on an at least abstract level. Such abstract
templates could then be adapted to the individual national or
local context. In the German sample it is remarkable that items
with a presumably high signiﬁcance for biobank research in gen-
eral (Cambon-Thomsen et al., 2007; Hansson, 2009; OECD, 2009;
Budimir et al., 2011) were mentioned in less than 25% of all con-
sent forms, e.g., “International Cooperation/trans-border use,”
“Right of access to personal data” and “Policy on use/disclosure to
third parties for non-research purpose.” The low coverage of such
issues in consent forms may be partly because new developments
in data protection law and research agendas are not foreseeable
in detail. But it may be also because of a still limited aware-
ness of legal, ethical, and practical challenges in biobank research
and the need for their transparent communication to potential
participants (Gottweis and Kaye, 2012).
Concerning the complexity of information, empirical studies
need to assess which potentially relevant content issues for consent
forms in biobank research can be condensed or simpliﬁed with-
out minimizing the validity of the consent and the tissue donors’
understanding of biobank research. For a ﬁrst step in this direction
see Beskow (Beskow et al., 2010).
Our study has the following limitations: as a demand of fur-
ther research it would be worthwhile to expand or modify the
guidance-based assessmentmatrix for consent in biobank research
in the following way: (1) to deﬁne a set of core criteria or bal-
ance the assessment items regarding their importance or relevance,
(2) to outline explaining dimensions for these items, and (3)
to further analyze which aspects are not covered sufﬁciently by
the matrix respectively by the included guidances (e.g., diagnos-
tic/therapeutic misconception). Such conceptual and empirical
research would provide the basis for a deeper evaluation of exist-
ing consent documents and for the development of new consent
documents. Within our explorative study of German biobank
consent documents we only considered whether a potentially rel-
evant content issue was mentioned in a consent form at all. We
evaluated neither the accuracy of the explanation of this issue
nor its quality, comprehensibility, or readability. Furthermore,
we did not assess criteria for supportive decision-making (e.g.,
IPDAS-criteria IPDAS, 2005; Elwyn et al., 2006). These assessment
criteria are certainly important for the development and evalua-
tion of valid consent procedures as shown e.g., by (Beskow et al.,
2010; Brehaut et al., 2012). Another limitation arises from the
fact that we could only include 32% of consent forms from the
full sample of 102 biobanks registered in the German Biobank
Registry. However, our sample of 30 consent forms included
all leading German biobanks with relatively high quality stan-
dards (including all six biobanks that are part of the National
Biobank Initiative funded by the German Federal Ministry of Edu-
cation and Research, BMBF). We suppose that the inclusion of
further consent forms would not have changed the overall pic-
ture of the strong heterogeneity of consent forms for biobank
research. Moreover,wewould even expect awider variation in con-
tent issues. Other investigations have reached similar results and
support the ﬁnding that consent material in general, or in biomed-
ical and biobank research in particular, needs improvement
(Padhy et al., 2011; Pawlikowski et al., 2011; Brehaut et al., 2012;
Mandava et al., 2012).
Taking into account the widely shared vision of national and
international networking of biobanks and increased activities in
data and sample sharing, our ﬁndings demonstrate the need of
improvement and harmonization of consent procedures in the
ﬁeld of biobank research. Furthermore, such improvements are
important to fulﬁl the demand of responsible biobank governance
and to maintain public trust in biobank research (Gottweis and
Kaye,2012). This does also include transparent communication on
consent procedures. As described in the methods section only nine
consent templates (8.8%) of the 102 initially identiﬁed biobanks
were available publically on the biobanks’ web sites. Furthermore,
even after repeated contact and the guarantee to anonymize the
results for our assessment of consent forms only 32% of reg-
istered German biobanks were willing to provide their present
consent form. Beside the need to improve and harmonize con-
sent procedures, increased transparency of such basic information
should become a major aim of German biobanks, to demonstrate
appropriate standards of governance.
When it comes to future improvement and harmonization of
consent forms, public attitudes and expert opinion in relevant
ﬁelds such as law, ethics, medicine, natural science etc. should
be sought to deﬁne core criteria for consent. It may also help to
overcome the lack of awareness of potentially relevant consent
items and to address them in an appropriate way.
CONCLUSION
Our ﬁndings serve as a starting point to reﬂect upon the spectrum
of relevant consent issues in biobank research. The present study
supports the systematic and transparent development of a “best
practice” model of consent for biobank research. The ﬁndings
show that at least the majority of consent documents in German
biobanks should be improved and harmonized to better support
an informed and balanced choice by potential donors and to facil-
itate research cooperation and networking. Further steps of such
a best practice model would include the development of a best
practice consent template (considering content, adherence to qual-
ity and language criteria) followed by a discussion and review of
the template with other stakeholders (e.g., researchers, research
ethics committees, potential biobank participants, patients’ rep-
resentatives, and ethicists). Especially for a best practice model
for consent forms, the understanding and validity of the text
should be tested empirically (Sugarman et al., 2005; Flory et al.,
2008). Finally, its use should be accompanied by continuous
evaluation.
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